SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Ranbaxy Laboratories
Ranbaxy Laboratories
BSE: 500359|NSE: RANBAXY|ISIN: INE015A01028|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
, 16:01
859.90
0
VOLUME 308,222
LIVE
NSE
, 16:01
859.80
0
VOLUME 5,415,702
Earnings News on Ranbaxy Laboratories
Select Year: 2013 |  2012 |  2011 | 2010 | 2009 | 2008 | 2007 | 2000-2006
Sun Pharma maintains 13-15% FY15 topline guidance: CFO 

2.54 pm | 18 Feb 2015 |  Source: CNBC-TV18

The company has grown faster than the market in India and would be focused on research and development (R&D) spends going forward, said Uday Baldota, ...

Operating performance may hurt Sun Pharma's Q3 profit: Poll

2.46 pm | 13 Feb 2015 |  Source: Moneycontrol.com

Sun Pharmaceutical Industries will announce its third quarter earnings on Saturday. According to a CNBC-TV18 poll, net profit of the drug maker may ri...

Ranbaxy Q3 disappoints; US mkt, Diovan led to loss: Angel 

3.08 pm | 28 Jan 2015 |  Source: CNBC-TV18

Speaking to CNBC-TV18, Sarabjit Kaur Nangra of Angel Broking said on the bottomline, margins suffered due to forex loss. The drug maker reported a for...

Ranbaxy posts Q3 loss of Rs 1030cr; revenue at Rs 2619cr 

2.49 pm | 28 Jan 2015 |  Source: Moneycontrol.com

Troubled pharmaceuticals firm Ranbaxy Laboratories consolidated posted a consolidated net loss of Rs 1,030 crore compared to Rs 159 crore in the same ...

Ranbaxy Labs Q3 revenue may rise 12% to Rs 3236 cr: Poll 

11.15 am | 28 Jan 2015 |  Source: CNBC-TV18

Ranbaxy Laboratories, which will soon become a part of Sun Pharma, will announce its third quarter (October-December) earnings today. Analysts expect ...

Merger with Ranbaxy might get delayed: Sun CFO Baldota 

11.59 am | 14 Nov 2014 |  Source: CNBC-TV18

The pharma major is hopeful of maintaining its revenue growth guidance of 13-15 percent for FY15 though the margins may get impacted marginally....

US core business continues to be a drag for Ranbaxy: CIMB 

9.05 am | 29 Oct 2014 |  Source: CNBC-TV18

Prakash Agarwal, Equity Analyst, CIMB has a hold rating on Ranbaxy with target price of Rs 630/share. ...

Here's how experts read Ranbaxy's Q2FY15 earnings

3.59 pm | 28 Oct 2014 |  Source: CNBC-TV18

Ranbaxy Laboratories has turned profitable in the second quarter of current financial year. The company reported consolidated net profit of Rs 478 cro...

Ranbaxy turns corner, Q2 net at Rs 478 cr; OPM up 1770 bps 

2.02 pm | 28 Oct 2014 |  Source: Moneycontrol.com

The company reported consolidated net profit of Rs 478 crore during the quarter as against loss of Rs 454 crore in the year-ago period....

1
Quick Links for Ranbaxy Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.